We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Former Celgene Shareholders Sue BMS for $6.4 Billion Over Alleged Lymphoma Drug Delay
Former Celgene Shareholders Sue BMS for $6.4 Billion Over Alleged Lymphoma Drug Delay
Bristol Myers Squibb (BMS) has been sued for $6.4 billion by former Celgene shareholders for allegedly delaying FDA approval of its cancer drug Breyanzi (lisocabtagene maraleuce).